99 related articles for article (PubMed ID: 15083368)
1. IL-6-174G/C genotype is associated with the bone mineral density response to oestrogen replacement therapy in post-menopausal women.
James L; Onambele G; Woledge R; Skelton D; Woods D; Eleftheriou K; Hawe E; Humphries SE; Haddad F; Montgomery H
Eur J Appl Physiol; 2004 Jun; 92(1-2):227-30. PubMed ID: 15083368
[TBL] [Abstract][Full Text] [Related]
2. Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women.
Han KO; Choi JT; Moon IG; Jeong MS; Yim CH; Chung HY; Jang HC; Yoon HK; Han IK
Bone; 2002 Nov; 31(5):612-5. PubMed ID: 12477576
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women.
Ongphiphadhanakul B; Chanprasertyothin S; Payatikul P; Tung SS; Piaseu N; Chailurkit L; Chansirikarn S; Puavilai G; Rajatanavin R
Clin Endocrinol (Oxf); 2000 May; 52(5):581-5. PubMed ID: 10792337
[TBL] [Abstract][Full Text] [Related]
4. Association of the G-174C variant in the interleukin-6 promoter region with bone loss and fracture risk in older women.
Moffett SP; Zmuda JM; Cauley JA; Stone KL; Nevitt MC; Ensrud KE; Hillier TA; Hochberg MC; Joslyn G; Morin P; Cummings SR;
J Bone Miner Res; 2004 Oct; 19(10):1612-8. PubMed ID: 15355555
[TBL] [Abstract][Full Text] [Related]
5. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
6. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
[TBL] [Abstract][Full Text] [Related]
7. COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.
MacDonald HM; McGuigan FA; New SA; Campbell MK; Golden MH; Ralston SH; Reid DM
J Bone Miner Res; 2001 Sep; 16(9):1634-41. PubMed ID: 11547832
[TBL] [Abstract][Full Text] [Related]
8. Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study.
Tofteng CL; Abrahamsen B; Jensen JE; Petersen S; Teilmann J; Kindmark A; Vestergaard P; Gram J; Langdahl BL; Mosekilde L
Calcif Tissue Int; 2004 Aug; 75(2):123-32. PubMed ID: 15129369
[TBL] [Abstract][Full Text] [Related]
9. Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
Yamada Y; Harada A; Hosoi T; Miyauchi A; Ikeda K; Ohta H; Shiraki M
J Bone Miner Res; 2000 Mar; 15(3):415-20. PubMed ID: 10750555
[TBL] [Abstract][Full Text] [Related]
10. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
11. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study.
Ferrari SL; Karasik D; Liu J; Karamohamed S; Herbert AG; Cupples LA; Kiel DP
J Bone Miner Res; 2004 Apr; 19(4):552-9. PubMed ID: 15005841
[TBL] [Abstract][Full Text] [Related]
12. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism.
Simsek M; Cetin Z; Bilgen T; Taskin O; Luleci G; Keser I
J Obstet Gynaecol Res; 2008 Feb; 34(1):73-7. PubMed ID: 18226133
[TBL] [Abstract][Full Text] [Related]
14. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
15. The association of IL-1beta, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women.
Czerny B; Kaminski A; Kurzawski M; Kotrych D; Safranow K; Dziedziejko V; Bohatyrewicz A; Pawlik A
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):82-5. PubMed ID: 20060205
[TBL] [Abstract][Full Text] [Related]
16. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
[TBL] [Abstract][Full Text] [Related]
18. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
19. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
[TBL] [Abstract][Full Text] [Related]
20. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
Heikkinen AM; Niskanen LK; Salmi JA; Koulu M; Pesonen U; Uusitupa MI; Komulainen MH; Tuppurainen MT; Kröger H; Jurvelin J; Saarikoski S
Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
